ArticleDiscover oncology2026
Integration of machine learning-based screening approaches and single-cell sequencing technique to identify cancer stemness genes associated with radiotherapy resistance in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy resistance in lung adenocarcinoma (LUAD) complicates treatment and worsens outcomes. Growing evidence indicates that cancer stemness contributes to radioresistance and poor prognosis. This study aimed to develop a prognostic model based on radioresistant stemness genes and to identify candidate therapeutics.
methodsMachine-learning methods were used to identify key radioresistant stemness genes (RRSKGs) and construct a prognostic risk score, the Radioresistant Stemness Risk Prognostic Score (RRSRPS). Its prognostic value was evaluated by Cox regression. PLK1 was prioritized for mechanistic analysis. Single-cell RNA sequencing and immune deconvolution characterized PLK1’s cellular distribution and associations with immune infiltration. Molecular docking and flow cytometry examined the relationship between cisplatin and PLK1. Clonogenic assays and xenograft models assessed whether cisplatin enhances radiosensitivity.
resultsRRSRPS was an independent prognostic factor. PLK1 was identified as the target through screening. Knockdown of PLK1 significantly suppressed cell viability and enhanced radiosensitivity, increasing apoptosis by 40.06 ± 1.524% versus control. Mechanistic studies showed PLK1 acts via the JAK-STAT3 pathway, confirmed by rescue experiments. Drug sensitivity analysis and molecular docking identified cisplatin as a specific PLK1 inhibitor. Clonogenic and in vivo assays demonstrated that cisplatin combined with radiotherapy synergistically inhibited tumor growth, reducing tumor volume by 697 ± 41.81 mm³ compared to control.
conclusionsRRSRPS is a robust, independent prognostic indicator in LUAD. Cisplatin increases radiosensitivity, potentially via PLK1-related mechanisms, offering a feasible precision-medicine strategy for patients with radioresistant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.